Susan Aherne, Mark Donnelly, Éanna J Ryan, Matthew G Davey, Ben Creavin, Erinn McGrath, Aoife McCarthy, Robert Geraghty, David Gibbons, Iris Nagtegaal, Alessandro Lugli, Richard Kirsch, Sean T Martin, Desmond C Winter, Kieran Sheahan
BACKGROUND: Tumour budding (TB) is a marker of tumour aggressiveness which, when measured in rectal cancer resection specimens, predicts worse outcomes and response to neoadjuvant therapy. We investigated the utility of TB assessment in the setting of neoadjuvant treatment. METHODS AND RESULTS: A single-centre, retrospective cohort study was conducted. TB was assessed using the hot-spot International Tumour Budding Consortium (ITBCC) method and classified by the revised ITBCC criteria...
April 17, 2024: Histopathology